News | February 11, 2021
J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Subscribe To Our Newsletter & Stay Updated
